Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy
Drug Design, Development and Therapy · 2023
DOI: 10.2147/dddt.s373546 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Tomoyuki Tatenuma und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Urology, University of Rochester Medical Center, Rochester, NY, USA.
ORCID-Profile: Hiroshi Miyamoto
Zitieren
APA
Tatenuma, T., & Miyamoto, H. (2023). Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s373546
Vancouver
Tatenuma T, Miyamoto H. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s373546
BibTeX
@article{Tatenuma2023,
author = {Tatenuma, Tomoyuki and Miyamoto, Hiroshi},
title = {Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy},
journal = {Drug Design, Development and Therapy},
year = {2023},
doi = {10.2147/dddt.s373546}
}
EUVIMED